Advertisement

Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study

  • Chikara IinoEmail author
  • Tetsu Endo
  • Kenichiro Mikami
  • Takuma Hasegawa
  • Masayo Kimura
  • Naoya Sawada
  • Shigeyuki Nakaji
  • Shinsaku Fukuda
Original Article

Abstract

Background

Compositional changes of the gut microbiota are known to occur in patients with nonalcoholic fatty liver disease (NAFLD); however, the changes did not corroborate between the studies. We evaluated the gut microbiota between NAFLD and non-NAFLD participants, excluding the influence of obesity and sex in this study involving a large number of participants.

Methods

In total, 1148 adults participated in the health survey. NAFLD was defined as fatty liver by ultrasonography in the absence of other causes of steatosis. To exclude the influence of obesity and sex, NAFLD participants were matched to non-NAFLD participants based on BMI and sex. The relative abundance of each bacterial taxa in fecal samples was calculated using 16S ribosomal RNA amplification and was compared between NAFLD and non-NAFLD participants.

Results

There were 205 (23.5%) participants defined as having NAFLD. Before matching, there were significant differences in the relative abundance of more than 1% in two classes, two orders, three families, and three genera including Faecalibacterium between NAFLD and non-NAFLD participants. After matching, 153 matched pairs were obtained. In terms of the relative abundance of more than 1%, the relative abundance of two taxa, including the family Ruminococcaceae and the genus Faecalibacterium, was significantly lower in NAFLD participants than in non-NAFLD participants (p = 0.016 and p = 0.018).

Conclusions

The significant decrease in Faecalibacterium is a remarkable characteristic on BMI- and sex-matched analysis in NAFLD participants in a large study population. The decrease in Faecalibacterium is related to the pathogenesis of NAFLD.

Keywords

Nonalcoholic fatty liver disease Gut microbiota Faecalibacterium 

Abbreviation

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

BMI

Body mass index

HbA1c

Hemoglobin A1c

HOMA-IR

Homeostasis model assessment of insulin resistance

LPS

Lipopolysaccharides

NAFLD

Nonalcoholic fatty liver disease

NASH

Nonalcoholic steatohepatitis

Notes

Acknowledgements

This study was based on the Iwaki Health Promotion Project as a project by Hirosaki University Graduate School of Medicine, in collaboration with Aomori Heath Evaluation and Promotion Center and Hirosaki City Office, Department of Health Promotion.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was performed in accordance with the ethical standards of the Declaration of Helsinki and was approved by the Hirosaki University Medical Ethics Committee.

Informed consent

Written informed consent was obtained from all participants.

References

  1. 1.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.CrossRefGoogle Scholar
  2. 2.
    Wiest R, Albillos A, Trauner M, et al. Targeting the gut–liver axis in liver disease. J Hepatol. 2017;67:1084–103.CrossRefGoogle Scholar
  3. 3.
    Tripathi A, Debelius J, Brenner DA, et al. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397–411.CrossRefGoogle Scholar
  4. 4.
    Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–9.CrossRefGoogle Scholar
  5. 5.
    Wong VW, Tse CH, Lam TT, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis: a longitudinal study. PLoS One. 2013;8:e62885.CrossRefGoogle Scholar
  6. 6.
    Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–7.CrossRefGoogle Scholar
  7. 7.
    Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:868–75.CrossRefGoogle Scholar
  8. 8.
    Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.CrossRefGoogle Scholar
  9. 9.
    Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054–62.CrossRefGoogle Scholar
  10. 10.
    Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16:375–81.CrossRefGoogle Scholar
  11. 11.
    Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–64.CrossRefGoogle Scholar
  12. 12.
    Odamaki T, Kato K, Sugahara H, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol. 2016;16:90.CrossRefGoogle Scholar
  13. 13.
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;21:1022–3.CrossRefGoogle Scholar
  14. 14.
    Borgo F, Garbossa S, Riva A, et al. Body mass index and sex affect diverse microbial niches within the gut. Front Microbiol. 2018;9:213.CrossRefGoogle Scholar
  15. 15.
    Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–15.CrossRefGoogle Scholar
  16. 16.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefGoogle Scholar
  17. 17.
    Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefGoogle Scholar
  18. 18.
    Shah AG, Lydecker A, Murray K, Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.CrossRefGoogle Scholar
  19. 19.
    Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing. PLoS One. 2014;9:e105592.CrossRefGoogle Scholar
  20. 20.
    Hisada T, Endoh K, Kuriki K. Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese. Arch Microbiol. 2015;197:919–34.CrossRefGoogle Scholar
  21. 21.
    Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16:255–61.CrossRefGoogle Scholar
  22. 22.
    Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731–6.CrossRefGoogle Scholar
  23. 23.
    De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:63.CrossRefGoogle Scholar
  24. 24.
    Dewulf EM, Cani PD, Claus SP, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013;62:1112–21.CrossRefGoogle Scholar
  25. 25.
    González-Sarrías A, Romo-Vaquero M, García-Villalba R, Cortés-Martín A, Selma MV, Espín JC. The endotoxemia marker lipopolysaccharide-binding protein is reduced in overweight-obese subjects consuming pomegranate extract by modulating the gut microbiota: a randomized clinical trial. Mol Nutr Food Res. 2018;62:e1800160.CrossRefGoogle Scholar
  26. 26.
    Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G518–25.CrossRefGoogle Scholar
  27. 27.
    Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, LeiteMoreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4:659–72.CrossRefGoogle Scholar
  28. 28.
    Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol. 2002;283:G256–65.CrossRefGoogle Scholar
  29. 29.
    Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.CrossRefGoogle Scholar
  30. 30.
    Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178:38–45.CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyHirosaki University Graduate School of MedicineHirosakiJapan
  2. 2.Department of Internal MedicineOwani HospitalOwaniJapan
  3. 3.Department of Social MedicineHirosaki University Graduate School of MedicineHirosakiJapan

Personalised recommendations